Fmr LLC Has $1.16 Billion Holdings in Moderna, Inc. (NASDAQ:MRNA)

Fmr LLC decreased its holdings in shares of Moderna, Inc. (NASDAQ:MRNA) by 17.9% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 17,382,165 shares of the company’s stock after selling 3,779,120 shares during the quarter. Fmr LLC owned approximately 4.52% of Moderna worth $1,161,650,000 as of its most recent SEC filing.

Other hedge funds have also added to or reduced their stakes in the company. Commerzbank Aktiengesellschaft FI raised its stake in shares of Moderna by 1.7% during the 2nd quarter. Commerzbank Aktiengesellschaft FI now owns 5,550 shares of the company’s stock worth $660,000 after purchasing an additional 93 shares in the last quarter. CVA Family Office LLC raised its position in Moderna by 21.6% during the second quarter. CVA Family Office LLC now owns 541 shares of the company’s stock worth $64,000 after acquiring an additional 96 shares in the last quarter. Claro Advisors LLC raised its position in Moderna by 2.0% during the second quarter. Claro Advisors LLC now owns 5,546 shares of the company’s stock worth $659,000 after acquiring an additional 108 shares in the last quarter. McAdam LLC grew its position in shares of Moderna by 1.1% in the 2nd quarter. McAdam LLC now owns 11,075 shares of the company’s stock valued at $1,315,000 after acquiring an additional 117 shares during the period. Finally, 180 Wealth Advisors LLC increased its stake in shares of Moderna by 1.1% during the 2nd quarter. 180 Wealth Advisors LLC now owns 14,868 shares of the company’s stock worth $1,826,000 after purchasing an additional 160 shares during the last quarter. Institutional investors own 75.33% of the company’s stock.

Insider Transactions at Moderna

In other Moderna news, CFO James M. Mock sold 715 shares of the business’s stock in a transaction that occurred on Monday, October 7th. The shares were sold at an average price of $60.12, for a total transaction of $42,985.80. Following the completion of the transaction, the chief financial officer now directly owns 9,505 shares in the company, valued at $571,440.60. The trade was a 7.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. In the last 90 days, insiders sold 1,147 shares of company stock valued at $76,245. Company insiders own 15.70% of the company’s stock.

Moderna Price Performance

Shares of NASDAQ MRNA opened at $43.39 on Thursday. The stock has a market capitalization of $16.70 billion, a PE ratio of -7.46 and a beta of 1.69. Moderna, Inc. has a fifty-two week low of $35.80 and a fifty-two week high of $170.47. The company has a debt-to-equity ratio of 0.05, a current ratio of 4.39 and a quick ratio of 4.20. The business has a fifty day moving average price of $53.32 and a two-hundred day moving average price of $92.28.

Moderna (NASDAQ:MRNA) last posted its quarterly earnings data on Thursday, November 7th. The company reported $0.03 earnings per share for the quarter, topping the consensus estimate of ($1.89) by $1.92. The business had revenue of $1.90 billion during the quarter, compared to analysts’ expectations of $1.25 billion. Moderna had a negative net margin of 43.77% and a negative return on equity of 17.68%. Moderna’s revenue was up 3.8% compared to the same quarter last year. During the same quarter in the prior year, the business posted ($1.39) earnings per share. As a group, equities analysts predict that Moderna, Inc. will post -9.44 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several equities research analysts recently issued reports on the stock. Needham & Company LLC reiterated a “hold” rating on shares of Moderna in a research note on Friday, November 8th. Royal Bank of Canada reiterated a “sector perform” rating and set a $75.00 target price on shares of Moderna in a research note on Thursday, September 19th. Bank of America decreased their target price on Moderna from $130.00 to $110.00 and set a “neutral” rating on the stock in a report on Friday, September 13th. Piper Sandler reaffirmed an “overweight” rating and set a $69.00 price target (down previously from $115.00) on shares of Moderna in a report on Monday, November 18th. Finally, Hsbc Global Res upgraded shares of Moderna from a “hold” rating to a “strong-buy” rating in a report on Monday, November 18th. Three investment analysts have rated the stock with a sell rating, thirteen have issued a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Hold” and a consensus target price of $83.26.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.